ABSTRACT Patients with asthma often wheeze at night and they also become hypoxic during sleep. To determine whether ketotifen, a drug with sedative properties, is safe for use at night in patients with asthma, we performed a double blind crossover study comparing the effects of a single 1 mg dose of ketotifen and of placebo on arterial oxygen saturation (Sao2), breathing patterns, electroencephalographic (EEG) sleep stage, and overnight change in FEV, in 10 patients with stable asthma. After taking ketotifen, the patients slept longer and their sleep was less disturbed than after taking placebo, true sleep occupying 387 (SEM 8) minutes after ketotifen and 336 (19) minutes after placebo (p<002). On ketotifen nights the patients had less wakefulness and drowsiness (EEG sleep stages 0 and 1) and more non-rapid eye movement (non-REM) sleep than on placebo nights, but the duration of REM sleep was similar on the two occasions. Nocturnal changes in Sao2, the duration of irregular breathing, and overnight change in FEVI were unaffected by ketotifen.
Patients with asthma often become wheezy at night, ' with an overnight fall in forced expiratory flow rates.2 They also sleep less well, become more hypoxaemic during the night, and have more irregular beathing during sleep than do hea'lthy people of similar age. 4 Drowsiness is a recognised side effect of ketotifen (Zaditen, Sandoz),5 and, since sleep is associated with hypoxaemia and irregular breathing in asthmatic patients we were concemed that ketotifen might have an adverse effect on patients with nocturnal asthma. We have therefore studied the effects of a single 1 mg dose of ketotifen on oxygenation, sleep quality, breathing patterns, and overnight change in one second forced expiratory volume (FEV,) during nocturnal sleep in 10 patients with stable asthma.
Methods
We made non-invasive measurements of electroencephalographic (EEG) sleep stage, breathing patterns, arterial oxygen saturation (Sao2), and overnight change in FEV, in 10 adult patients with stable asthma during nocturnal sleep in a double blind crossover trial of ketotifen. The trial was designed so that half the patients received placebo before ketotifen and half received ketotifen first. The patients slept in a quiet, darkened room on two pairs of two consecutive nights (the first serving as an acclimatisation night) separated by two to four weeks. The patients (nine men and one woman, aged 18-55 years) all had airways obstruction that was reversible and varied spontaneously. During the two years before the study the lowest FEV, recorded in each subject at the outpatient clinic ranged from 0-5 to 1*9 1 and the highest spontaneous FEV, from 1-7 to 4-2 1. Eight of the patients had positive skinprick test responses to at least two common allergens, including Dermatophagoides pteronyssinus, and six had a family history of atopy. All the patients inhaled a beta2 agonist, six inhaled beclomethasone dipropionate, and three took regular oral prednisolone in a dose of 5 mg daily. (7) minutes after placebo. Most (99%) of this irregular breathing was hypopnoea. In all 10 subjects only nine episodes of apnoea occurred after placebo and 11 after ketotifen. All the apnoeic episodes were of central type.
ARTERIAL OXYGEN SATURATION
Sao2 during sleep was also unaltered by ketotifen. The change in Sao2 from the level before sleep (ketotifen nights 96 4% (0.7%); placebo nights 95-6% (0.9%)) to the lowest level during sleep (ketotifen 88-4% (1-2%); placebo 88.1% (1-6%)) was the same after the drug (8-0% (1 1 %)) and after placebo (7.8% (1.2%)). Significant episodes of hypoxaemia (defined as falls in Sao2 of at least 4% from the immediately preceding stable Sao2) occurred in six patients from once to nine times (mean 2*4 times) a night on placebo. The number of episodes was not significantly different on ketotifen nights, when six patients had from one to 12 (mean 2.6) hypoxaemic episodes a night.
OVERNIGHT CHANGE IN FEV,
The FEVI before sleep averaged 2-9 (0.4) 1 on ketotifen nights and 2*9 (0.4) 1 on placebo nights. In all patients the lower of these values was within 30% of the higher. After taking ketotifen none of the patients asked to use an inhaler during the night. After taking placebo, however, four of the 10 patients required their beta2 agonist inhalers before going back to sleep (p<0 1, X2 test for. small numbers).9 Three of these awakenings occurred between 3.00 and 3.30 am and the other at 5.35 am. The FEV1 recorded at these times was on average 1.0 1 (range 0.3-1-7 1) lower than the FEV, before sleep. In the other six patients the FEV, was on average 0-6 1 lower after sleep than before sleep when they had taken placebo, compared with a fall of 0-9 1 with ketotifen. This difference (fig 2) was not significant.
Discussion
Ketotifen had no significant adverse effect on oxygenation and breathing patterns during sleep or on overnight change in FEV, when given as a single 1 mg dose to our 10 adult patients with stable asthma at night. Furthermore, our patients slept longer and spent more time in the deeper stages of sleep after taking ketotifen than after taking placebo.
It is not clear how ketotifen helps asthmatic patients to sleep. The drug has both antiallergic and antihistaminic properties. ' Beta2 agonists were withheld on the nights of our study, to separate the effects of ketotifen from those of sympathomimetic drugs. We do not know whether ketotifen would have the same effects on EEG sleep stage when given in combination with beta2 agonists.
Ketotifen has been described as protecting against acute antigen challenge'2 and histamine challenge '3 in asthmatic patients but there is debate whether it provides effective prophylaxis against asthmatic attacks in clinical practice.'4 '" The cause of nocturnal asthma is not known, but a rise in plasma histamine has been associated with bronchoconstriction at 4 am'8 and early morning peak expiratory flow rate has been reported to improve with allergen avoidance. '9 Ketotifen failed to improve the overnight change in FEV, in our patients. This, however, could reflect the fact that we gave only a single 1 mg dose, for a protective effect of ketotifen has been described with prolonged administration of 2 mg a day. 20 The morning fall in peak expiratory flow in asthma can be reduced by long acting beta2 agonists2' and theophyllines. 2' 22 Both are stimulants of the central nervous system, however, and can interfere with sleep.23 25 We would recommend that drugs used in the treatment of nocturnal asthma should be assessed not only for their effects on nocturnal bronchoconstriction but also for their therapeutic value in treating the disturbed sleep experienced by these patients.
